High Note Wealth’s AstraZeneca AZN Stock Holding History

High Note Wealth’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.3K	Hold	239	–	–	0.01%	209
2026 Q1	$47.1K	Sell	239 -1	-0.4%	-$193	0.01%	196
2025 Q4	$44.1K	Hold	240	–	–	0.01%	196
2025 Q3	$36.8K	Buy	240 +53	+28%	+$8.02K	0.01%	199
2025 Q2	$26.1K	Hold	187	–	–	0.01%	222
2025 Q1	$27.4K	Hold	187	–	–	0.01%	214
2024 Q4	$24.4K	Buy	+187	New	+$26.2K	0.01%	215

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

High Note Wealth's AZN Position: Q2 2026 in Review

High Note Wealth held its AstraZeneca (AZN) position steady in Q2 2026 at 239 shares worth $45.3K. The position accounts for 0.01% of the portfolio, ranked #209.

High Note Wealth first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. The position peaked at $47.1K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

High Note Wealth held 239 shares of AstraZeneca worth $45.3K as of Q2 2026.
High Note Wealth left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of High Note Wealth's portfolio in Q2 2026, its #209 holding.
High Note Wealth first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
High Note Wealth's AstraZeneca position peaked at $47.1K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on High Note Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.